“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Aprecia Pharmaceuticals


Aprecia Pharmaceuticals products

Spritam (levetiracetam tablets for oral suspension)
Indication: Adjunctive therapy for partial onset seizures, myoclonic seizures, and primary generalized tonic–clonic seizures in epilepsy
Status: First—and currently only—FDA-approved medication manufactured using 3D-printing (ZipDose technology); rapidly disintegrates with a small sip of liquid and is deliverable via NG- and G-tubes

ZipDose Technology
Description: Proprietary 3D-printing platform that enables oral dosage forms with high dose loads that dissolve quickly (even at large tablet sizes)
Application: Used to formulate Spritam and potentially adaptable for other high-dose, easy-swallow drug delivery solutions




on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)